Animalcare Group plc (ANCR) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Animal Care Group PLC investor presentation. Throughout this recorded presentation, investors will be in listen-only mode. Questions are encouraged and can be submitted at any time via the Q&A tab situated on the right-hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll. I'd now like to hand you over to Jenny Winter, CEO. Good afternoon. Good afternoon and thank you very much. And you're very welcome to our interim results 2025 presentation. You have myself and Chris Brewster. I know that we've met several of you previously and looking forward to taking you through the short presentation and answering any questions you may have. For those of you who haven't listened to one of our presentations before, who aren't familiar with us, We're an international veterinary pharmaceutical company. The majority of our products are prescription products. So they're either used by the vet in the vet surgery. So anesthesia, analgesic, anesthetics, et cetera. They're prescribed to a pet owner. So the vet writes a prescription. Very often we'll sell the product based on that prescription. And in some of our products, they don't need a prescription, but the vet will send the pet owner home with a product. We operate in all three segments of the veterinary pharmaceutical market. Companion animals, so dogs and cats mainly. And that's the biggest part of our business, as you can see on the right hand side. That's growing at about 4 percent. Difficult to get very accurate data, but around 4 percent....